Document:

Unassociated Document

EXHIBIT 10.1

 

INTELLECTUAL PROPERTY ASSIGNMENT & LICENSE AGREEMENT

 

THIS INTELLECTUAL PROPERTY ASSIGNMENT & LICENSE AGREEMENT (this “Agreement”) is made and dated as of June 21, 2011 (the “Effective Date”) by and between CARDIOGENICS INC., an Ontario corporation with its principal office and place of business at 6295 Northam Drive, Unit 8, Mississauga, Ontario L4V 1W8 Canada (“CardioGenics”) and LUXSPHERES INC., an Ontario corporation with its principal office and place of business at 6295 Northam Drive, Unit 8, Mississauga, Ontario L4V 1W8 Canada (“Luxspheres”).

 

WHEREAS, CardioGenics has (a) developed proprietary magnetic microspheres and nanospheres and certain related proprietary technologies, which can be utilized to enhance the light scattering and light collection efficiency of its proprietary magnetic microspheres and nanospheres, as well as the magnetic microspheres and nanospheres of third-parties and (b) entered into commercial and material transfer agreements with certain third party beads manufacturers and distributors in connection with such proprietary technologies;

 

WHEREAS, CardioGenics believes that it would be able to more effectively develop the business for such technologies if such business was operated through its own subsidiary;

 

WHEREAS, CardioGenics has established Luxspheres, as its wholly-owned subsidiary, from which such business will be operated and, therefore, desires to assign to Luxspheres CardioGenics’ interests in the above-referenced proprietary technologies and its related intellectual property and agreements;

 

WHEREAS, CardioGenics also desires to obtain from Luxspheres, simultaneous with such assignment, a worldwide, perpetual, royalty-free and transferable license to use the beads technologies in connection with CardioGenics’ QL CareTM Analyzer or any other point-of-care diagnostic device or platform that may hereafter be developed or commercialized by CardioGenics or any of its successors or assigns (the “CardioGenics POC Platform”);

 

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows:

 

	
1. 

	
DEFINITIONS.

 

“Beads” shall mean the CardioGenics Beads and the Third-Party Beads.

 

“Beads Agreements” shall mean that certain agreement between Merck Chimie S.A and CardioGenics dated January 19, 2009, as amended, and all material transfer agreements and any other agreements entered into between CardioGenics and any third party in connection with the Beads Technology.

 

“Beads Intellectual Property” shall mean any and all (a) patent, copyright, trademark, service mark and other intellectual property rights of any kind anywhere in the world related to, derived from or in connection with the Beads Technology and (b) rights of action, powers and benefits arising from the ownership of such intellectual property, including, without limitation, the right to sue for damages and other legal and equitable remedies for any past, current or future infringement or violation of such intellectual property rights.

 

  

  

  

 

“Beads Technology” shall mean any and all data, writings (irrespective of whether in written or electronic form), information (tangible and intangible), processes, methods, inventions, discoveries, improvements, trade secrets, works of authorship and technology in any form whatsoever, including, without limitation, certain proprietary technologies utilized to enhance the light scattering and light collection efficiency of the CardioGenics Beads and any Third Party Beads, generated, made, created or developed by, or on behalf of, CardioGenics for use in connection with the CardioGenics Beads and any Third Party Beads.

 

“CardioGenics Beads” shall mean the proprietary magnetic microspheres and nanospheres developed by CardioGenics.

 

“Goodwill” shall mean the goodwill of the business symbolized by the Beads Technology, the Beads Intellectual Property, the Beads Agreements and the Product Lots.

 

“Product Lots” shall mean any existing quantities of (a) CardioGenics Beads (naked or encapsulated by CardioGenics); (b) CardioGenics Beads encapsulated by any third party beads manufacturer or distributor pursuant to any Beads Agreements); (c) Third Party Beads incorporating CardioGenics’ Beads Technology pursuant to any Beads Agreements; and (d) any other CardioGenics Beads not intended for use in the CardioGenics POC Platform.

 

“Third-Party Beads” shall mean the magnetic microspheres and nanospheres owned or licensed by any third party manufacturers or distributors.

 

2.            ASSIGNMENT. CardioGenics hereby assigns, transfers and delivers to Luxspheres, its successors and assigns, all right, title and interest of CardioGenics, anywhere in the world, in and to (the “Assignment”):

 

(a)           The Beads Technology;

 

(b)           The Beads Intellectual Property;

 

(c)           The Beads Agreements: and

 

(d)           The Product Lots.

 

3.            ASSUMPTION OF OBLIGATIONS UNDER BEADS AGREEMENTS. Luxspheres hereby assumes all duties and obligations of CardioGenics under the Beads Agreements and agrees to perform such obligations in accordance with the terms of the Beads Agreements.

 

  

  

  

 

4.            LICENSE TO CARDIOGENICS.  (a) Subject to the terms and conditions of this Agreement, and effective immediately following the Assignment, Luxspheres hereby grants to CardioGenics an exclusive, perpetual, royalty-free, worldwide right and license to use, employ, develop, sublicense and commercialize the Beads Technology (and any enhancements to such technology hereafter developed by Luxspheres or its successors and assigns) solely for the purposes of (i) developing microspeheres or nanospheres for use in the CardioGenics POC Platform or any other point-of-care diagnostic platform for which CardioGenics may, in its sole discretion, choose to sublicense the Beads Technology (collectively, the “POC Platforms”) and (ii) selling, sublicensing or otherwise commercializing the POC Platforms based on or utilizing the Beads Technology  (the “CardioGenics License”).

 

(b) In furtherance of the CardioGenics License, Luxspheres, agrees not to license (or permit any party, other than CardioGenics, to sublicense) the Beads Technology or the Beads Intellectual Property to any party for use in any point-of-care diagnostic platform.

 

5.            FURTHER ASSURANCES AND ASSISTANCE.  (a) Upon prior written request by Luxspheres and at Luxspheres’ expense, CardioGenics agrees to perform any and all acts and execute any and all documents in such manner and at such location as may be required by Luxspheres in its discretion to: (i) protect, perfect or enforce any of the rights, privileges and entitlements granted or promised to Luxspheres under this Agreement; and (ii) enable Luxspheres to pursue or prosecute any intellectual property application, registration or other filing in respect of the Beads Technology or the Beads Intellectual Property in favor of Luxspheres or such other party as Luxspheres may designate, including, without limitation, signing and executing any formal assignment or other related documents as may be required by any relevant intellectual property registries anywhere in the world.

 

(b)  If CardioGenics shall have failed, following 5 days' written notice from Luxspheres, to perform any act or execute any document referred to in this Section 5 (a) above, Luxspheres shall have the right to do so in the place and stead of CardioGenics as its lawfully appointed attorney-in-fact and CardioGenics hereby irrevocably appoints Luxspheres as its attorney-in-fact for such purposes.

 

(c) CardioGenics undertakes to reasonably cooperate with Luxspheres in any proceedings for infringement of any Beads Intellectual Property rights, including providing such information as Luxspheres may reasonably request, provided that Luxspheres shall reimburse CardioGenics for any costs or expenses incurred by CardioGenics in providing such cooperation.

 

6.            DISCLAIMERS. (a) THE ASSIGNMENT OF THE BEADS TECHNOLOGY, THE BEADS INTELLECTUAL PROPERTY, THE BEADS AGREEMENTS AND THE PRODUCT LOTS, AS WELL AS THE CARDIOGENICS LICENSE, HAVE BEEN PROVIDED TO THE RESPECTIVE PARTIES ON AN “AS IS” BASIS, WITHOUT ANY WARRANTY WHATSOEVER, AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR ARISING FROM CUSTOM OR TRADE, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.

 

(b)  NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL OR EXEMPLARY DAMAGES ARISING UNDER OR OUT OF THE ASSIGNMENT HEREUNDEROR OR THE CARDIOGENICS LICENSE, REGARDLESS OF WHETHER ADVISED BEFOREHAND OF THE POSSIBILITY OF SUCH DAMAGES.

 

  

  

  

 

7.            AUTHORIZATION.   CardioGenics and Luxspheres each represent and warrant to the other as follows:

 

(a)  That it has full power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and

 

(b)  That this Agreement has been duly executed and delivered by it and constitutes its valid and legally binding obligation enforceable in accordance with its terms; and  

 

(c)  It is a corporation organized under the laws of the Province of Ontario, in good standing, and has obtained all consents and other approvals necessary under Ontario law, its Articles of Incorporation, and its Bylaws necessary for the execution, delivery and performance of this Agreement.

 

8.            MISCELLANEOUS.

 

(a)  No Third-Party Beneficiaries. The terms and provisions of this Agreement are intended solely for the benefit of the parties hereto and their respective successors and permitted assigns, and it is not the intention of the parties to confer third-party beneficiary rights upon any other person or entity, and this Agreement does not confer any such rights.

 

(b) Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes any prior understandings, agreements or representations by or between the parties hereto, written or oral, with respect to such subject matter.

 

(c)  Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. No party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other party. Any such purported assignment in violation of the above provisions shall null and void.

 

  

  

  

 

(d)  Drafting.  The parties have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

(e) Notices.  All notices, requests and other communications hereunder must be in writing and will be deemed to have been duly given only if delivered personally against written acknowledgement of receipt or by facsimile transmission or mailed (by registered or certified mail, postage prepaid, return receipt requested) or delivered by reputable overnight courier, fee prepaid, to the parties hereto at the following addresses or facsimile numbers:

 

  

 

	
If to CardioGenics, to:

	
CardioGenics Inc.

6295 Northam Drive, Unit 8

Mississauga, Ontario L4V 1W8 

Attention: Dr. Yahia Gawad, President

905.673.9865 (fax)

 

	
If to Luxspheres, to: 

	
Luxspheres Inc.

 6295 Northam Drive, Unit 8

Mississauga, Ontario L4V 1W8 

Attention: Dr. Yahia Gawad, President

905.673.9865   (fax)

 

 

 Any party hereto may change the address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other party hereto notice in the manner set forth herein.

(f)  Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the Province of Ontario, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the Province of Ontario.

(g)  Amendments and Waivers.  No amendment of any provision of this Agreement shall be valid unless such amendment is in writing and signed by each of the parties hereto. No waiver by any party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No waiver shall be valid unless such waiver is in writing and signed by the party against whom such waiver is sought to be enforced.

 

  

  

  

(h)  Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of any party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms of such illegal, invalid or unenforceable provision as may be possible without materially and adversely affecting any of the parties hereto.

(i)  Specific Performance.  The parties hereto agree that irreparable damage would occur in the event that any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof in addition to any other remedy available to them at law or equity.

(j)  Headings. The descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

(k)  Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

 

{SIGNATURES APPEAR ON FOLLOWING PAGE}

 

  

  

  

 

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first written above.

 

	CARDIOGENICS INC.	 	LUXSPHERES INC.	 
	 	 	 	 	 	 
	
By: 

	/s/ Yahia Gawad	 	By:	
/s/ Linda J. Sterling

	 
	 	Name: Yahia Gawad	 	 	
Name: Linda J. Sterling

	 
	
 

	Title: President	 	 	

Title: Director & Corporate SecretaryGENERAL CANNABIS, INC.

THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“THE ACT”), OR THE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (ii) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (iii) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE.

COMMON STOCK PURCHASE WARRANT

THIS IS TO CERTIFY that, for value received, Crystal Research Associates, LLC (the “Holder”) is entitled, subject to the terms and conditions set forth herein, to purchase from General Cannabis, Inc., (f/k/a LC Luxuries Ltd.), a Nevada corporation (the “Company”) up to Two Hundred Fifty Thousand (250,000) fully paid and nonassessable shares of common stock of the Company (the “Warrant Securities”) at the initial price of $4.00 per share but subject to adjustment as provided in Section 3 below, (the “Exercise Price”), upon payment by cashier’s check or wire transfer of the Exercise Price for such shares of the Common Stock to the Company at the Company’s offices.

This Warrant is being issued to Holder as consideration under that certain Letter of Agreement between Holder and the Company dated October 5, 2010.

1.           Exercisability.  This Warrant may be exercised in whole or in part at any time, or from time to time, between the date hereof and October 5, 2014 by presentation and surrender hereof to the Company of a notice of election to purchase duly executed and accompanied by payment by check or wire transfer of the Exercise Price..

2.           Manner of Exercise.  In case of the purchase of less than all the Warrant Securities, the Company shall cancel this Warrant upon the surrender hereof and shall execute and deliver a new warrant of like tenor for the balance of the Warrant Securities.  Upon the exercise of this Warrant, the issuance of certificates for securities, properties or rights underlying this Warrant shall be made forthwith (and in any event within five (5) business days thereafter) without charge to the Holder including, without limitation, any tax that may be payable in respect of the issuance thereof: provided, however, that the Company shall not be required to pay any tax in respect of income or capital gain of the Holder.

  

Page 1 of 6

 

 

If and to the extent this Warrant is exercised, in whole or in part, the Holder shall be entitled to receive a certificate or certificates representing the Warrant Securities so purchased, upon presentation and surrender to the Company of the form of election to purchase attached hereto duly executed, and accompanied by payment of the purchase price.

3.           Adjustment in Number of Shares.

(A)           Adjustment for Reclassifications.  In case at any time or from time to time after the issue date the holders of the Common Stock of the Company (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received, or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without payment therefore, other or additional stock or other securities or property (including cash) by way of stock split, spin-off, reclassification, combination of shares or similar corporate rearrangement (exclusive of any stock dividend of its or any subsidiary’s capital stock), then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1, shall be entitled to receive the amount of stock and other securities and property which such Holder would hold on the date of such exercise if on the issue date he had been the holder of record of the number of shares of Common Stock of the Company called for on the face of this Warrant and had thereafter, during the period from the issue date, to and including the date of such exercise, retained such shares and/or all other or additional stock and other securities and property receivable by him as aforesaid during such period, giving effect to all adjustments called for during such period.  In the event of any such adjustment, the Exercise Price shall be adjusted proportionally.

(B)           Adjustment for Reorganization, Consolidation, Merger.  In case of any reorganization of the Company (or any other corporation the stock or other securities of which are at the time receivable on the exercise of this Warrant) after the issue date, or in case, after such date, the Company (or any such other corporation) shall consolidate with or merge into another corporation or convey all or substantially all of its assets to another corporation, then and in each such case the Holder of this Warrant, upon the exercise hereof as provided in Section 1 at any time after the consummation of such reorganization, consolidation, merger or conveyance, shall be entitled to receive, in lieu of the stock or other securities or property to which such Holder would be entitled had the Holder exercised this Warrant immediately prior thereto, all subject to further adjustment as provided herein; in each such case, the terms of this Warrant shall be applicable to the shares of stock or other securities or property receivable upon the exercise of this Warrant after such consummation.

4.           No Requirement to Exercise.  Nothing contained in this Warrant shall be construed as requiring the Holder to exercise this Warrant.

5.           No Stockholder Rights.  Unless and until this Warrant is exercised, this Warrant shall not entitle the Holder hereof to any voting rights or other rights as a stockholder of the Company, or to any other rights whatsoever except the rights herein expressed, and, no dividends shall be payable or accrue in respect of this Warrant.

 

  

Page 2 of 6

 

 

6.           Exchange.  This Warrant is exchangeable upon the surrender hereof by the Holder to the Company for new warrants of like tenor representing in the aggregate the right to purchase the number of Warrant Securities purchasable hereunder, each of such new warrants to represent the right to purchase such number of Warrant Securities as shall be designated by the Holder at the time of such surrender.

Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it and reimbursement to the company of all reasonable expenses incidental thereto, and upon surrender and cancellation hereof, if mutilated, the Company will make and deliver a new warrant of like tenor and amount, in lieu hereof.

7.           Elimination of Fractional Interests.  The Company shall not be required to issue certificates representing fractions of securities upon the exercise of this Warrant, nor shall it be required to issue scrip or pay cash in lieu of fractional interests.  All fractional interests shall be eliminated by rounding any fraction up to the nearest whole number of securities, properties or rights receivable upon exercise of this Warrant.

8.           Reservation of Securities.  The Company shall at all times reserve and keep available out of its authorized shares of Common Stock or other securities, solely for the purpose of issuance upon the exercise of this Warrant, such number of shares of Common Stock or other securities, properties or rights as shall be issuable upon the exercise hereof.  The Company covenants and agrees that, upon exercise of this Warrant and payment of the Principal Value, all shares of Common Stock and other securities issuable upon such exercise shall be duly and validly issued, fully paid, non-assessable and not subject to the preemptive rights of any stockholder.

9.           Notices to Holder.  If at any time prior to the expiration of this Warrant or its exercise, any of the following events shall occur:

(a)           the Company shall take a record of the holders of any class of its securities for the purpose of entitling them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of current or retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company; or

(b)           the Company shall offer to all the holders of a class of its securities any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option or warrant to subscribe therefor; or

(c)           a dissolution, liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially all of its property, assets and business as an entirety shall be proposed.

 

  

Page 3 of 6

 

 

then, in any one or more said events, the Company shall give written notice of such event to the Holder at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the stockholder entitled to such dividend, distribution, convertible or exchangeable securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale.  Such notice shall specify such record date or the date of closing the transfer books, as the case may be.

10.           Transferability.  This Warrant may not be transferred or assigned by the Holder without the express written consent of the Company.

11.           Informational Requirements.  The Company will transmit to the Holder such information, documents and reports as are generally distributed to stockholders of the Company concurrently with the distribution thereof to such stockholders.

12.           Notice.  Notices to be given to the Company or the Holder shall be deemed to have been sufficiently given if delivered personally or sent by overnight courier or messenger, or by facsimile transmission.  Notices shall be deemed to have been received on the date of personal delivery or facsimile transmission.  The address of the Company and of the Holder shall be as set forth in the Company’s books and records.

13.           Consent to Jurisdiction and Service.  The Company consents to the jurisdiction of any court of the State of California, and of any federal court located in California, in any action or proceeding arising out of or in connection with this Warrant.  The Company waives personal service of any summons, complaint or other process in connection with any such action or proceeding and agrees that service thereof may be made at the location provided in Section 12 hereof, or, in the alternative, in any other form or manner permitted by law.  Orange County, California shall be proper venue.

14.           Successors.  All the covenants and provisions of this Warrant shall be binding upon and inure to the benefit of the Company, the Holder and their respective legal representatives, successors and assigns.

15.           Attorneys Fees.  Should either party commence any action, suit or proceeding to enforce this Warrant or any term or provision hereof, then in addition to any other damages or awards that may be granted to the prevailing party, the prevailing party shall be entitled to have and recover from the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in connection therewith.

16.           Governing Law.  THIS WARRANT SHALL BE GOVERNED, CONSTRUED AND INTERPRETED UNDER THE LAWS OF THE STATE OF CALIFORNIA, WITHOUT GIVING EFFECT TO THE RULES GOVERNING CONFLICTS OF LAW.

 

  

Page 4 of 6

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by the signature of its Chief Executive Officer and to be delivered in Newport Beach, California.

	
Dated: April 13, 2011

	
General Cannabis, Inc.,

	 
	  	
a Nevada corporation

	 
	  	  	 
	  	
/s/  James Pakulis

	 
	  	
By:

	
James Pakulis

	 
	  	
Its:

	
Chief Executive Officer

	 

Acknowledged:

Crystal Research Associates, LLC

	
/s/  signature illegible

	
By:

	  
	
Its:

	  

 

  

Page 5 of 6

 

 

[FORM OF ELECTION TO PURCHASE]

The undersigned, the holder of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by this Warrant Certificate for, and to purchase securities of General Cannabis, Inc. and herewith makes payment of $__________ therefor, and requests that the certificates for such securities be issued in the name of, and delivered to ___________________, whose address is ______________________________.

Dated: ____________________, 20___

	  	  	  
	  	
By:

	  
	  	
Its:

	  
	  	
(Signature must conform in all respects to name of holder as specified on the face of the Warrant Certificate)

	  	  	  
	  	  	  
	  	
(Insert Social Security or Other

	  	
Identifying Number of Holder)

 

  

Page 6 of 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]